PharmaEngine, Inc. is a biopharmaceutical company established in Taipei, Taiwan in 2003 principally engaged in the research and development of anticancer drugs. The Company's anticancer drugs are used in the treatment of pancreas cancer, gastric cancer, large intestine and rectal cancer, lung cancer, as well as cerebral cancer. As of December 31, 2011, the Company obtained its major revenue from product warranty transfer fee.PharmaEngine adopts the business model of no research, development only and focuses on the development of new drugs for the treatment of cancer and Asian prevalent diseases. The lead project PEP02 (nanoliposomal irinotecan, aka MM-398) which was licensed to Merrimack Pharmaceuticals, Inc., (Cambridge, MA, USA), is in a global phase III study for the treatment of metastatic pancreatic cancer; the second is PEP503 (crystalline hafnium oxide, aka NBTXR3) from Nanobiotix, Inc. (Paris, France); and the third was a collaboration with Guangzhou BeBetter Medicine Technology, Co., Ltd. (Guangzhou, China).
